NCT06958926 A Translational Study for Locoregional Recurrence of T4 Colon Cancer
| NCT ID | NCT06958926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | T4 Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-14 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-05-14 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The outcome of T4 locally advanced colon cancer is poor when locoregional recurrence occurred. Previous studies had showed that the aggravation of T4 colon cancer is higher than N-positive colon cancer, contributing to staging paradox that outcomes of stage IIB/C are poorer than stage IIIA colon cancer and higher locoregional recurrence of stage IIB/C colon cancer. The phenomenon cannot be explained by radicality, lymph node harvested and adjuvant chemotherapy administration. To elucidate the cancerous aggravation of T4 colon cancer, the investigators should dive into the clinicopathology, metastatic mechanism and cancer biology. The investigators hypothesize that peritoneal spreading can be one of the metastatic routes of T4 colon cancer; however, few studies have addressed the finding and deserved investigation. Previous research have found that serum epigenetic alterations and cell-free DNA can serve as a prognostic marker for stage II/III colon cancer. Therefore, the aim of this study is (1) to explore the role of ascites cfDNA as a potential biomolecular marker for locoregional recurrence; (2) to identify the risk factors of locoregional recurrence for T4 colon cancer by correlating biomolecular markers between clinicopathology, epigenomic alterations in blood and ascites.
Eligibility Criteria
* Inclusion Criteria: 1. Age ≥ 18 years old 2. Diagnosed as colorectal cancer 3. Undergo radical colectomy or palliative colectomy, not limited to minimally invasive surgery or open surgery * Exclusion Criteria: 1. Age\<18 years old 2. Pregnancy 3. Patients with peritoneal dialysis 4. Patients who are unwilling to undergo colorectal surgery
Contact & Investigator
Yu-Tso Liao, MD, PhD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital Hsin-Chu Branch
Frequently Asked Questions
Who can join the NCT06958926 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying T4 Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06958926 currently recruiting?
Yes, NCT06958926 is actively recruiting participants. Contact the research team at G02386@hch.gov.tw for enrollment information.
Where is the NCT06958926 trial being conducted?
This trial is being conducted at Hsinchu, Taiwan.
Who is sponsoring the NCT06958926 clinical trial?
NCT06958926 is sponsored by National Taiwan University Hospital. The principal investigator is Yu-Tso Liao, MD, PhD at National Taiwan University Hospital Hsin-Chu Branch. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.